Pharma & Healthcare
Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Research Report 2026
- Mar 17, 26
- ID: 741381
- Pages: 90
- Figures: 95
- Views: 2
This report delivers a comprehensive overview of the global Fusion Protein Anti-VEGF Ophthalmic Drugs market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Fusion Protein Anti-VEGF Ophthalmic Drugs. The Fusion Protein Anti-VEGF Ophthalmic Drugs market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.
The report segments the global Fusion Protein Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Fusion Protein Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Chengdu Kanghong Pharmaceutical
Segment by Type
Aflibercept
Conbercept
by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Fusion Protein Anti-VEGF Ophthalmic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Fusion Protein Anti-VEGF Ophthalmic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
The report segments the global Fusion Protein Anti-VEGF Ophthalmic Drugs market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.
This report will assist Fusion Protein Anti-VEGF Ophthalmic Drugs manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.
Market Segmentation
By Company
Regeneron Pharmaceuticals
Samsung Bioepis
Biocon Biologics
Chengdu Kanghong Pharmaceutical
Segment by Type
Aflibercept
Conbercept
by Application
Hospital and Clinic
Retail Pharmacies
Other
Consumption by Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Fusion Protein Anti-VEGF Ophthalmic Drugs manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Fusion Protein Anti-VEGF Ophthalmic Drugs sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.
1 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Overview
1.1 Product Definition
1.2 Fusion Protein Anti-VEGF Ophthalmic Drugs by Type
1.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Aflibercept
1.2.3 Conbercept
1.3 Fusion Protein Anti-VEGF Ophthalmic Drugs by Application
1.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue 2021–2032
1.4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales 2021–2032
1.4.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Fusion Protein Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
2.8 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Scenario by Region
3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2032
3.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2026
3.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2027–2032
3.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2032
3.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2026
3.3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2027–2032
3.4 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.4.3 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.5.3 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2032)
4.1.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2026)
4.1.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2027–2032)
4.1.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2032)
4.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2026)
4.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2027–2032)
4.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2032)
5.1.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2026)
5.1.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2027–2032)
5.1.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2032)
5.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2026)
5.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2027–2032)
5.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Company Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Samsung Bioepis
6.2.1 Samsung Bioepis Company Information
6.2.2 Samsung Bioepis Description and Business Overview
6.2.3 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.2.5 Samsung Bioepis Recent Developments/Updates
6.3 Biocon Biologics
6.3.1 Biocon Biologics Company Information
6.3.2 Biocon Biologics Description and Business Overview
6.3.3 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.3.5 Biocon Biologics Recent Developments/Updates
6.4 Chengdu Kanghong Pharmaceutical
6.4.1 Chengdu Kanghong Pharmaceutical Company Information
6.4.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.4.3 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.4.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Chain Analysis
7.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Production Mode & Process Analysis
7.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales and Marketing
7.4.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Channels
7.4.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors
7.5 Fusion Protein Anti-VEGF Ophthalmic Drugs Customer Analysis
8 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Dynamics
8.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Trends
8.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Drivers
8.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Challenges
8.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Definition
1.2 Fusion Protein Anti-VEGF Ophthalmic Drugs by Type
1.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type: 2025 vs 2032
1.2.2 Aflibercept
1.2.3 Conbercept
1.3 Fusion Protein Anti-VEGF Ophthalmic Drugs by Application
1.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application: 2025 vs 2032
1.3.2 Hospital and Clinic
1.3.3 Retail Pharmacies
1.3.4 Other
1.4 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size Estimates and Forecasts
1.4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue 2021–2032
1.4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales 2021–2032
1.4.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Average Price (2021–2032)
1.5 Assumptions and Limitations
2 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competition by Manufacturers
2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Manufacturers (2021–2026)
2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price by Manufacturers (2021–2026)
2.4 Global Key Players of Fusion Protein Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
2.5 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
2.6 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Product Types and Applications
2.7 Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
2.8 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competitive Situation and Trends
2.8.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Concentration Rate
2.8.2 The Top 5 and Top 10 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Players Market Share by Revenue
2.8.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Company Tier (Tier 1, Tier 2, Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Scenario by Region
3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2032
3.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2021–2026
3.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region: 2027–2032
3.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2032
3.3.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021–2026
3.3.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2027–2032
3.4 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.4.1 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.4.2 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.4.3 North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.4.4 United States
3.4.5 Canada
3.5 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.5.1 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.5.2 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.5.3 Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region: 2021 vs 2025 vs 2032
3.6.2 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (2021–2032)
3.6.3 Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (2021–2032)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.7.1 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.7.2 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.7.3 Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.7.7 Colombia
3.8 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Country: 2021 vs 2025 vs 2032
3.8.2 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (2021–2032)
3.8.3 Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (2021–2032)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2032)
4.1.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2021–2026)
4.1.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Type (2027–2032)
4.1.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2032)
4.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2032)
4.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2021–2026)
4.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Type (2027–2032)
4.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2032)
4.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price by Type (2021–2032)
5 Segment by Application
5.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2032)
5.1.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2021–2026)
5.1.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Application (2027–2032)
5.1.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2032)
5.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2032)
5.2.1 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2021–2026)
5.2.2 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Application (2027–2032)
5.2.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2032)
5.3 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price by Application (2021–2032)
6 Key Companies Profiled
6.1 Regeneron Pharmaceuticals
6.1.1 Regeneron Pharmaceuticals Company Information
6.1.2 Regeneron Pharmaceuticals Description and Business Overview
6.1.3 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.1.4 Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.1.5 Regeneron Pharmaceuticals Recent Developments/Updates
6.2 Samsung Bioepis
6.2.1 Samsung Bioepis Company Information
6.2.2 Samsung Bioepis Description and Business Overview
6.2.3 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.2.4 Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.2.5 Samsung Bioepis Recent Developments/Updates
6.3 Biocon Biologics
6.3.1 Biocon Biologics Company Information
6.3.2 Biocon Biologics Description and Business Overview
6.3.3 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.3.4 Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.3.5 Biocon Biologics Recent Developments/Updates
6.4 Chengdu Kanghong Pharmaceutical
6.4.1 Chengdu Kanghong Pharmaceutical Company Information
6.4.2 Chengdu Kanghong Pharmaceutical Description and Business Overview
6.4.3 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales, Revenue, and Gross Margin (2021–2026)
6.4.4 Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product Portfolio
6.4.5 Chengdu Kanghong Pharmaceutical Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Chain Analysis
7.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Production Mode & Process Analysis
7.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales and Marketing
7.4.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Channels
7.4.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors
7.5 Fusion Protein Anti-VEGF Ophthalmic Drugs Customer Analysis
8 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Dynamics
8.1 Fusion Protein Anti-VEGF Ophthalmic Drugs Industry Trends
8.2 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Drivers
8.3 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Challenges
8.4 Fusion Protein Anti-VEGF Ophthalmic Drugs Market Restraints
8.5 Impact of U.S. Tariffs
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of Tables
Table 1. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Fusion Protein Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Regeneron Pharmaceuticals Company Information
Table 71. Regeneron Pharmaceuticals Description and Business Overview
Table 72. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 74. Regeneron Pharmaceuticals Recent Developments/Updates
Table 75. Samsung Bioepis Company Information
Table 76. Samsung Bioepis Description and Business Overview
Table 77. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 79. Samsung Bioepis Recent Developments/Updates
Table 80. Biocon Biologics Company Information
Table 81. Biocon Biologics Description and Business Overview
Table 82. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 84. Biocon Biologics Recent Developments/Updates
Table 85. Chengdu Kanghong Pharmaceutical Company Information
Table 86. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 87. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 89. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors List
Table 93. Fusion Protein Anti-VEGF Ophthalmic Drugs Customers List
Table 94. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Trends
Table 95. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Drivers
Table 96. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Challenges
Table 97. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Fusion Protein Anti-VEGF Ophthalmic Drugs
Figure 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Conbercept Product Picture
Figure 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), 2021–2032
Figure 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose), 2021–2032
Figure 15. Fusion Protein Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 16. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Fusion Protein Anti-VEGF Ophthalmic Drugs in 2025
Figure 19. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2032)
Figure 58. Fusion Protein Anti-VEGF Ophthalmic Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Table 1. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2025 vs 2032
Table 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2025 vs 2032
Table 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Competitive Situation by Manufacturers in 2025
Table 4. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) of Key Manufacturers (2021–2026)
Table 5. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Manufacturers (2021–2026)
Table 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Manufacturers (2021–2026)
Table 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers (2021–2026)
Table 8. Global Market Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose) of Key Manufacturers (2021–2026)
Table 9. Global Key Players of Fusion Protein Anti-VEGF Ophthalmic Drugs, Industry Ranking, 2023 vs 2024 vs 2025
Table 10. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Manufacturing Sites and Headquarters
Table 11. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Product Types and Applications
Table 12. Global Key Manufacturers of Fusion Protein Anti-VEGF Ophthalmic Drugs, Date of Entry into the Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Companies by Tier (Tier 1, Tier 2, Tier 3), based on Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, 2025
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Table 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 18. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2026)
Table 19. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2027–2032)
Table 21. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 22. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2026)
Table 23. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 24. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2027–2032)
Table 25. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 26. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 27. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 28. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 29. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 30. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 31. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 32. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 33. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 34. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 35. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 36. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2021–2026
Table 37. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Region (K Dose), 2027–2032
Table 38. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2021–2026
Table 39. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Region (US$ Million), 2027–2032
Table 40. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 43. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 44. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 45. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 46. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2021–2026
Table 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales by Country (K Dose), 2027–2032
Table 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2021–2026
Table 49. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue by Country (US$ Million), 2027–2032
Table 50. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2021–2026)
Table 51. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Type (2027–2032)
Table 52. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2021–2026)
Table 53. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Type (2027–2032)
Table 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2021–2026)
Table 55. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Type (2027–2032)
Table 56. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2021–2026)
Table 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Type (2027–2032)
Table 58. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2026)
Table 59. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2027–2032)
Table 60. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2021–2026)
Table 61. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose) by Application (2027–2032)
Table 62. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2021–2026)
Table 63. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Application (2027–2032)
Table 64. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2021–2026)
Table 65. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue (US$ Million) by Application (2027–2032)
Table 66. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2021–2026)
Table 67. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Application (2027–2032)
Table 68. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2026)
Table 69. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2027–2032)
Table 70. Regeneron Pharmaceuticals Company Information
Table 71. Regeneron Pharmaceuticals Description and Business Overview
Table 72. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 73. Regeneron Pharmaceuticals Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 74. Regeneron Pharmaceuticals Recent Developments/Updates
Table 75. Samsung Bioepis Company Information
Table 76. Samsung Bioepis Description and Business Overview
Table 77. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 78. Samsung Bioepis Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 79. Samsung Bioepis Recent Developments/Updates
Table 80. Biocon Biologics Company Information
Table 81. Biocon Biologics Description and Business Overview
Table 82. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 83. Biocon Biologics Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 84. Biocon Biologics Recent Developments/Updates
Table 85. Chengdu Kanghong Pharmaceutical Company Information
Table 86. Chengdu Kanghong Pharmaceutical Description and Business Overview
Table 87. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)
Table 88. Chengdu Kanghong Pharmaceutical Fusion Protein Anti-VEGF Ophthalmic Drugs Product
Table 89. Chengdu Kanghong Pharmaceutical Recent Developments/Updates
Table 90. Key Raw Materials Lists
Table 91. Raw Materials Key Suppliers Lists
Table 92. Fusion Protein Anti-VEGF Ophthalmic Drugs Distributors List
Table 93. Fusion Protein Anti-VEGF Ophthalmic Drugs Customers List
Table 94. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Trends
Table 95. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Drivers
Table 96. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Challenges
Table 97. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Restraints
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
Table 101. Authors List of This Report
List of Figures
Figure 1. Product Picture of Fusion Protein Anti-VEGF Ophthalmic Drugs
Figure 2. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Type (US$ Million), 2021–2032
Figure 3. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Type: 2025 & 2032
Figure 4. Aflibercept Product Picture
Figure 5. Conbercept Product Picture
Figure 6. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Value by Application (US$ Million), 2021–2032
Figure 7. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Application: 2025 & 2032
Figure 8. Hospital and Clinic
Figure 9. Retail Pharmacies
Figure 10. Other
Figure 11. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 12. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size (US$ Million), 2021–2032
Figure 13. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Sales (K Dose), 2021–2032
Figure 14. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Average Price (US$/Dose), 2021–2032
Figure 15. Fusion Protein Anti-VEGF Ophthalmic Drugs Report Years Considered
Figure 16. Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Share by Manufacturers in 2025
Figure 17. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Share by Manufacturers in 2025
Figure 18. Top 5 and Top 10 Global Fusion Protein Anti-VEGF Ophthalmic Drugs Players: Market Share by Revenue in Fusion Protein Anti-VEGF Ophthalmic Drugs in 2025
Figure 19. Fusion Protein Anti-VEGF Ophthalmic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025
Figure 20. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Market Size by Region (US$ Million): 2021 vs 2025 vs 2032
Figure 21. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 22. North America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 23. United States Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 24. Canada Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 25. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 26. Europe Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 27. Germany Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 28. France Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 29. U.K. Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 30. Italy Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 31. Russia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 32. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Region (2021–2032)
Figure 33. Asia Pacific Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Region (2021–2032)
Figure 34. China Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 35. Japan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 36. South Korea Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 37. India Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 38. Australia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 39. China Taiwan Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 40. Southeast Asia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 41. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 42. Latin America Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 43. Mexico Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 44. Brazil Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 45. Argentina Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 46. Colombia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 47. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Sales Market Share by Country (2021–2032)
Figure 48. Middle East and Africa Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Market Share by Country (2021–2032)
Figure 49. Turkey Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 50. Saudi Arabia Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 51. UAE Fusion Protein Anti-VEGF Ophthalmic Drugs Revenue Growth Rate (US$ Million), 2021–2032
Figure 52. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 53. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Type (2021–2032)
Figure 54. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Type (2021–2032)
Figure 55. Global Sales Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 56. Global Revenue Market Share of Fusion Protein Anti-VEGF Ophthalmic Drugs by Application (2021–2032)
Figure 57. Global Fusion Protein Anti-VEGF Ophthalmic Drugs Price (US$/Dose) by Application (2021–2032)
Figure 58. Fusion Protein Anti-VEGF Ophthalmic Drugs Value Chain
Figure 59. Channels of Distribution (Direct Vs Distribution)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
Global Smart Grid Digital Substation Market Research Report 2026
Mar 17, 26
Global Photovoltaic Molded Case Circuit Breaker Market Research Report 2026
Mar 17, 26
Global Roll-Roll Automobile Business Market Research Report 2026
Mar 17, 26
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232